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Contrary to classical dogma,molecular epidemiological studies andmathematicalmodeling
clearly show that the global drug-resistant tuberculosis (TB) epidemic is driven by transmis-
sion. Furthermore, there is mounting evidence demonstrating that amplification of resis-
tance occurs during treatment, possibly as a result of insufficient active drugs being
administered. To control the drug-resistant TB epidemic, it will be essential to implement
new, rapid, and highly sensitive and specific diagnostic methods to decrease the diagnostic
delay associated with culture-based testing. To date, three molecular-based diagnostic tests
havebeenendorsedby theWorldHealthOrganization:MTBDRplus (HainLifescience,Nehren,
Germany) Xpert MTB/RIF (Cepheid, Sunnyvale, United States) MTBDRsl (Hain Lifescience,
Nehren, Germany). Implementation of the MTBDRplus assay reduced the laboratory
turnaround time from 55 days to 27 days. This was further reduced to 1 day with the imple-
mentation of the Xpert MTB/RIF assay. However, time to initiation of multidrug-resistant
TB (MDR-TB) treatment was not significantly reduced, remaining at approximately 17 days
from receipt of drug-susceptibility testing (DST) results. In an attempt to reduce the time to
initiation of MDR-TB treatment, some guidelines have recommended initiating MDR-TB
treatment based on the diagnosis of rifampicin resistance alone (within 5 days). However,
this implies treating MDR-TB blindly until routine culture-based DST results are available
(mean, 54 days). This strategy may be highly effective in countries where second-line treat-
ment has only recently been introduced, butmay have significant consequences for patients
with resistancebeyondMDR-TB sensu stricto. Implementation of theMTBDRslassaypromises
to reduce the time forDST for fluoroquinolones and second-line injectable drugs. These tests
will formthe foundation forDST for the implementationof the recently recommendedshort-
ened MDR-TB regimen. The impact of the implementation of these tests on treatment out-
come using either the standard or shortened MDR-TB remains to be determined.Conflicts of interest
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